Paving the Way for Stem Cell Therapies

Scale Your Cell Culture Up to 100 Billion Cells per Batch
Discover How

Accelerating the Future of Cell & Gene Therapy

At CytoNiche, we specialize in simplifying the complex world of CGT, especially mesenchymal stem/stromal cells (MSCs) to drive the success of therapeutic commercialization. Our solutions empower you to scale up production with cost-effective, high-quality cells, so that you can focus on what you do best —— developing transformative therapeutics. By optimizing access and affordability, we accelerate the timeline for bringing groundbreaking products to market.

See What Powers Us >

We Offer

Featured Products

Events & News

More Events&News >

CytoNiche Receives Top Bioprocessing Honour at ABEA 2026

Mar 12,2026

CytoNiche Receives Top Bioprocessing Honour at ABEA 2026

Cytoniche Honoured with "Emerging Bioprocessing Supplier Award: Downstream Processing" at ABEA 2026
Japan Makes History with World's First Approval of iPS Cell Therapies

Mar 09,2026

Japan Makes History with World's First Approval of iPS Cell Therapies

Japan approved the world’s first iPS cell therapies in 2026 to treat heart failure and Parkinson’s disease, marking a major milestone for regenerative medicine.
When the Process Is the Product: Mastering Change Management in MSC and CAR-T Development

Mar 04,2026

When the Process Is the Product: Mastering Change Management in MSC and CAR-T Development

How can process changes in MSC and CAR-T therapy manufacturing be strategically managed to accelerate regulatory approval and enhance commercial competitiveness?

We are always looking forward to hear from you.

Security verification
Submit Your Request